These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

416 related items for PubMed ID: 11877262

  • 21. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
    Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M.
    Cancer; 2002 May 15; 94(10):2653-62. PubMed ID: 12173333
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
    Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, Rios MB, Shan J, Letvak L, Thomas D, Faderl S, Ferrajoli A, Cortes J.
    Blood; 2004 Apr 15; 103(8):2873-8. PubMed ID: 15070658
    [Abstract] [Full Text] [Related]

  • 25. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
    Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, O'Brien SG.
    Blood; 2002 Sep 15; 100(6):1965-71. PubMed ID: 12200353
    [Abstract] [Full Text] [Related]

  • 26. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.
    N Engl J Med; 2006 Jun 15; 354(24):2531-41. PubMed ID: 16775234
    [Abstract] [Full Text] [Related]

  • 27. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.
    Faber E, Nausová J, Jarosová M, Egorin MJ, Holzerová M, Rozmanová S, Maresová I, Divoký V, Indrák K.
    Leuk Lymphoma; 2006 Jun 15; 47(6):1082-90. PubMed ID: 16840200
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
    Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP.
    Blood; 2007 Mar 15; 109(6):2303-9. PubMed ID: 17138817
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.
    Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, Countouriotis A, Shah N.
    Blood; 2007 Jun 15; 109(12):5143-50. PubMed ID: 17317857
    [Abstract] [Full Text] [Related]

  • 33. Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
    Cervera E, Candelaria M, López-Navarro O, Labardini J, Gonzalez-Fierro A, Taja-Chayeb L, Cortes J, Gordillo-Bastidas D, Dueñas-González A.
    Clin Lymphoma Myeloma Leuk; 2012 Jun 15; 12(3):207-12. PubMed ID: 22420986
    [Abstract] [Full Text] [Related]

  • 34. Initial treatment for patients with CML.
    Goldman JM.
    Hematology Am Soc Hematol Educ Program; 2009 Jun 15; ():453-60. PubMed ID: 20008231
    [Abstract] [Full Text] [Related]

  • 35. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC, Zheng D, Li QH, Li XH, Cai CC, Luo SK, Li J, Peng AH, Tong XZ, Tan EX, Hong WD.
    Ai Zheng; 2004 Dec 15; 23(12):1696-9. PubMed ID: 15601563
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib.
    Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, Gillis K, Woodman RC, Blakesley RE, Giles FJ, Kantarjian HM, Baccarani M.
    Blood; 2011 May 26; 117(21):5600-6. PubMed ID: 21467546
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
    Cervantes F, Hernández-Boluda JC, Steegmann JL, Conde E, Alvarez-Larrán A, López-Jiménez J, Osorio S, Villalón L, Camós M, García-Conde J, Odriozola J.
    Haematologica; 2003 Oct 26; 88(10):1117-22. PubMed ID: 14555307
    [Abstract] [Full Text] [Related]

  • 40. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
    Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE.
    Clin Lymphoma Myeloma Leuk; 2014 Apr 26; 14(2):155-162.e1. PubMed ID: 24332214
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.